Almac Discovery is a research driven drug discovery company dedicated to the development of novel and innovative approaches to the treatment of diseases of unmet need (including oncology and CNS), by applying a target class approach. The Almac Discovery business model is to develop preclinical stage assets which are then licenced to pharmaceutical or biotech partners for further development. We also look to collaborate with partners to apply our medicinal chemistry and translational biology expertise to targets of mutual interest. Key research themes include deubiquitinase enzymes and protein drug conjugates.
CytoSeek's mission is to use Artificial Membrane Binding Protein technology to deliver the potential of the next generation of cell therapies, with a focus on treating solid tumours.
The company was founded in November 2017 to commercialise the technology developed by Professor Adam Perriman and his team at the University of Bristol.
CytoSeek is now engaged in proof of principle studies for multiple product candidates, and is seeking to enhance cell therapies against solid tumours.